FI963781A - Eristettyjä, MAGE-3-peräisiä peptidejä, jotka kompleksoivat HLA-A2-molekyylejä, ja niiden käyttöjä - Google Patents

Eristettyjä, MAGE-3-peräisiä peptidejä, jotka kompleksoivat HLA-A2-molekyylejä, ja niiden käyttöjä Download PDF

Info

Publication number
FI963781A
FI963781A FI963781A FI963781A FI963781A FI 963781 A FI963781 A FI 963781A FI 963781 A FI963781 A FI 963781A FI 963781 A FI963781 A FI 963781A FI 963781 A FI963781 A FI 963781A
Authority
FI
Finland
Prior art keywords
mage
hla
molecules
isolated
derived peptides
Prior art date
Application number
FI963781A
Other languages
English (en)
Swedish (sv)
Other versions
FI963781A0 (fi
Inventor
Der Bruggen Pierre Van
Thierry Boon-Falleur
Catia Traversari
Katharina Fleischauer
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of FI963781A publication Critical patent/FI963781A/fi
Publication of FI963781A0 publication Critical patent/FI963781A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI963781A 1994-03-24 1996-09-23 Eristettyjä, MAGE-3-peräisiä peptidejä, jotka kompleksoivat HLA-A2-molekyylejä, ja niiden käyttöjä FI963781A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,187 US5554506A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
PCT/US1995/003408 WO1995025739A1 (en) 1994-03-24 1995-03-21 Isolated, mage-3 derived peptides which complex with hla-a2 molecules and uses thereof

Publications (2)

Publication Number Publication Date
FI963781A true FI963781A (fi) 1996-09-23
FI963781A0 FI963781A0 (fi) 1996-09-23

Family

ID=22810011

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963781A FI963781A0 (fi) 1994-03-24 1996-09-23 Eristettyjä, MAGE-3-peräisiä peptidejä, jotka kompleksoivat HLA-A2-molekyylejä, ja niiden käyttöjä

Country Status (16)

Country Link
US (3) US5554506A (fi)
EP (1) EP0759032B1 (fi)
JP (1) JP3451356B2 (fi)
CN (1) CN1142177C (fi)
AT (1) ATE183195T1 (fi)
AU (1) AU682956B2 (fi)
CA (1) CA2186005A1 (fi)
DE (1) DE69511399T2 (fi)
DK (1) DK0759032T3 (fi)
ES (1) ES2135051T3 (fi)
FI (1) FI963781A0 (fi)
GR (1) GR3031811T3 (fi)
NZ (1) NZ283543A (fi)
TW (1) TW496875B (fi)
WO (1) WO1995025739A1 (fi)
ZA (1) ZA952376B (fi)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5827073A (en) * 1995-07-05 1998-10-27 Ludwig Institute For Cancer Research Photoreactive peptide derivatives
US6087441A (en) 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
CA2295321C (en) * 1997-06-23 2008-01-29 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
ATE391726T1 (de) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd Modifiziertes gp100 und dessen verwendung
US20020164654A1 (en) * 2000-01-20 2002-11-07 Rosalie Luiten MAGE antigenic peptides which bind HLA-B35 and HLA-B44
WO2001085932A2 (en) 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
WO2003085087A2 (en) 2002-04-09 2003-10-16 Aventis Pasteur, Limited Modified cea nucleic acid and expression vectors
EP2314712B1 (en) * 2001-11-07 2014-01-08 Mannkind Corporation Expression vectors encoding epitopes of antigens and methods for their design
US20070105779A1 (en) * 2002-07-31 2007-05-10 Danila Valmori Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
JP4668919B2 (ja) * 2003-10-08 2011-04-13 サノフィ パストゥール インコーポレイテッド 修飾ｃｅａ／ｂ７ベクター
KR101304243B1 (ko) * 2005-08-09 2013-09-05 온코세라피 사이언스 가부시키가이샤 ＨＬＡ-Ａ2 양성 환자용 글리피칸-3(ｇｌｙｐｉｃａｎ-3)유래의 암 거절항원 펩티드 및 그를 포함하는 의약
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
EP2480572B1 (en) 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
NZ255683A (en) * 1992-08-07 1996-08-27 Cytel Corp Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
NZ263050A (en) * 1993-03-05 1997-11-24 Cytel Corp Compositions of immunogenic peptides with hla-a2.1 binding motifs
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

Also Published As

Publication number Publication date
EP0759032B1 (en) 1999-08-11
JP3451356B2 (ja) 2003-09-29
CA2186005A1 (en) 1995-09-28
JPH10500667A (ja) 1998-01-20
FI963781A0 (fi) 1996-09-23
DK0759032T3 (da) 1999-12-27
WO1995025739A1 (en) 1995-09-28
EP0759032A1 (en) 1997-02-26
US5554506A (en) 1996-09-10
GR3031811T3 (en) 2000-02-29
NZ283543A (en) 1998-04-27
ES2135051T3 (es) 1999-10-16
DE69511399T2 (de) 2000-05-11
ZA952376B (en) 1995-12-14
TW496875B (en) 2002-08-01
ATE183195T1 (de) 1999-08-15
US6019987A (en) 2000-02-01
AU2187095A (en) 1995-10-09
EP0759032A4 (en) 1997-04-09
AU682956B2 (en) 1997-10-23
CN1142177C (zh) 2004-03-17
CN1151167A (zh) 1997-06-04
US6353089B1 (en) 2002-03-05
DE69511399D1 (de) 1999-09-16

Similar Documents

Publication Publication Date Title
FI963781A (fi) Eristettyjä, MAGE-3-peräisiä peptidejä, jotka kompleksoivat HLA-A2-molekyylejä, ja niiden käyttöjä
CA2186004A1 (en) Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
FI963780A0 (fi) Kasvainhyljintäantigeeniprekursorista MAGE-2 saatuja eristettyjä peptidejä ja niiden käyttöjä
ES2080717T3 (es) Hibridomas productores de anticuerpos monoclonales para nuevos epitopos de mucina.
FI950887A (fi) MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt
BR0015224A (pt) Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
ZA95786B (en) Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 recombinant mage-1 and mage-1 derived immunogeni peptides
WO1999004265A8 (en) Cancer associated nucleic acids and polypeptides
HUT38300A (en) Process for producing growth-controlling composition attached to the platelets
EP0845032A4 (en) ISOLATED NUCLEIC ACID MOLECULES, PEPTIDES FORMING COMPLEXES WITH THE MOLECULE OF THE MAJOR HLA-A2 HISTOCOMPATIBILITY COMPLEX (MHC) AND THEIR APPLICATIONS
EP1361271A3 (en) Isolated nonapeptide derived from MAGE-3 gene and presented by HLA-A1, and uses thereof
IL187595A (en) Pharmaceutical preparation containing monoclonal antibody - tumors and production
NO965087L (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
NO963917L (no) Isolerte, MAGE-3-avledete peptider som komplekserer med HLA-A2-molekyler, samt anvendelser derav
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
Townsend et al. Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
CA2308142A1 (en) Anti-idiotype monoclonal antibodies, their use in active immunotherapy of malignant tumors and compositions containing them